RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Number of tuberculosis patients in the Netherlands increased in 2023 compared to 2022 In 2023, 710 people in the Netherlands were diagnosed with tuberculosis (TB). This was 12 per cent more than in 2022, when there were 634. In 2023, 471 patients had pulmonary TB. Of these 417 patients, 213 had open TB – the most contagious type.
No changes to chromium (VI) adverse health effect list No changes will be made to the list of adverse health effects that may be caused by exposure to chromium (VI) in the workplace. According to RIVM, the latest scientific literature has resulted in no new insights.
Night shift workers more likely to have poor work-life balance People who work at night are more than 2.5 times more likely to have a poor work-life balance. They find it more difficult to combine their jobs and private lives than people who only work in daytime. This is one of the results of a study by RIVM and TNO.
Number of tuberculosis patients in the Netherlands decreased slightly in 2022 compared to 2021 The number of people with tuberculosis (TB) in the Netherlands decreased slightly in 2022. In 2022, there were 635 TB patients in the Netherlands. This is six per cent fewer than in 2021, when there were 673 patients.
RIVM and TNO describe impact of future developments on occupational health and safety RIVM and the Netherlands Organisation for Applied Scientific Research (TNO) have investigated the potential impact of developments in the next 20 years on occupational health and safety. How will artificial intelligence affect safety at work? iStock
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Vaccine manufacturer employee contracts poliovirus An employee of vaccine manufacturer Bilthoven Biologicals (BBio) has been infected with a poliovirus. The virus was found in a stool sample provided by the employee. The employee concerned is now in isolation.
Annual report ‘Tuberculosis in the Netherlands’ for 2021: slight increase in number of TB patients In 2021, the number of tuberculosis (TB) patients in the Netherlands rose slightly compared to the preceding year: up to 680 TB patients from 622 in 2020. However, the 2021 number was lower than the number for 2019 (754 patients).